KLDO News and Press, Kaleido Biosciences Inc. From 01/09/20

Kaleido Biosciences ( KLDO -4.4% ) will collaborate with Johnson & Johnson ( JNJ +0.2% ) unit Janssen Biotech to explore the potential of Kaleido's Microbiome Metabolic Therapies (MMT) to prevent childhood allergies and other atopic immune and metabolic conditions via driving speci...

LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the initiation of a research c...

LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Alison Lawton, President and ...

CAMBRIDGE, Mass. , Dec. 19, 2019 /PRNewswire/ --   Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based...

Thinly traded micro cap Kaleido Biosciences ( KLDO +10.5% ) is up on below-average volume, a modest 39K shares, on the heels of its  announced  advancement of candidate KB174 for the potential treatment of hepatic encephalopathy , a decline in brain function due to severe liver ...

- KB174 Exceeded the Targeted Reduction in a Biomarker of Microbiome Ammonia Production - KB174 Was Well Tolerated and No Clinically Significant or Serious Treatment-Related Adverse Events Were Observed LEXINGTON, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc ....

Gainers:  JanOne (NASDAQ: JAN ) +103% . More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...

Gainers:  Akerna (NASDAQ: KERN ) +47% . More news on: Akerna Corp., Mmtec, Inc., Melinta Therapeutics, Inc., Stocks on the move, Read more ...

LEXINGTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duk...

Kaleido Biosciences (NASDAQ: KLDO ): Q3 GAAP EPS of -$0.74 beats by $0.13 . More news on: Kaleido BioSciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...